Thomas K Henthorn

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Topics

Health Insurance

Cystic Fibrosis

Smoking Cessation

Top Venues

Clinical toxicology (Philadelphia, Pa.)

Therapeutic drug monitoring

British journal of clinical pharmacology

Drug testing and analysis

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas K Henthorn, George S Wang, Greg Dooley, Ashley Brooks-Russell, Julia Wrobel, Sarah Limbacher, Michael Kosnett
Dose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily Users. Therapeutic drug monitoring (2024)
Michael J Kosnett, Ming Ma, Gregory Dooley, George Sam Wang, Kyle Friedman, Timothy L Brown, Thomas K Henthorn, Ashley Brooks-Russell
Blood cannabinoid molar metabolite ratios are superior to blood THC as an indicator of recent cannabis smoking. Clinical toxicology (Philadelphia, Pa.) 61 (5) (2023)
John M Rague, Ming Ma, Gregory Dooley, George Sam Wang, Kyle Friedman, Thomas K Henthorn, Ashley Brooks-Russell, Michael J Kosnett
The minor cannabinoid cannabigerol (CBG) is a highly specific blood biomarker of recent cannabis smoking. Clinical toxicology (Philadelphia, Pa.) (2023)
Cristina Sempio, Marilyn A Huestis, Bruce Kaplan, Jost Klawitter, Uwe Christians, Thomas K Henthorn
Urinary clearance of 11-nor-9-carboxy-Δ 9 -tetrahydrocannabinol: A detailed pharmacokinetic analysis. Drug testing and analysis 14 (8) (2022)
Cristina Sempio, Marilyn A Huestis, Susan K Mikulich-Gilbertson, Jost Klawitter, Uwe Christians, Thomas K Henthorn
Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. British journal of clinical pharmacology 86 (3) (2020)